Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
[DATE] Patient: [PATIENT_FIRST_NAME] [PATIENT_LAST_NAME] Insurance Company: [INSURANCE_COMPANY_NAME] Subscriber Name: [POLICY_HOLDER_NAME] Policy #: [POLICY_NUMBER] Dear Claims Specialist, I am writing this letter on behalf of my patient, [PATIENT_FIRST_NAME] [PATIENT_LAST_NAME], to request coverage for the OncoGeneDx Endometrial Cancer panel, a genetic test offered through GeneDx, a high complexity CLIA certified laboratory located in Gaithersburg, Maryland. Personal and Family History: [PATIENT_FIRST_NAME] is a [PATIENT_AGE] year-old [PATIENT_GENDER] suspected to have a hereditary predisposition to cancer. [MR./MS.] [PATIENT_LAST_NAME] was diagnosed with XX cancer at age XX years. [HIS_HER] family history is remarkable for (discuss family history). [MR./MS.] [PATIENT_LAST_NAME]’s (personal and/or family) history is suggestive of a hereditary cancer syndrome. However, the only way to thoroughly assess this patient’s future cancer risks is to perform genetic testing. The results of this genetic test will have a direct impact on this patient’s treatment and management. Test Information and Impact of Results on Medical Management: As you are aware, multiple genes and cancer syndromes are associated with hereditary endometrial cancer. The OncoGeneDx Endometrial Cancer panel includes analysis of highly penetrant genes affecting endometrial cancer risk. Panel testing utilizes next generation sequencing technology, which allows for analysis of multiple genes simultaneously. This is far more cost effective and timely than stepwise genetic testing (for example, ordering testing of one or two genes followed by additional genetic tests, if negative). An additional benefit of the OncoGeneDx Endometrial Cancer panel is the ability to test for multiple hereditary cancer syndromes at once. Many hereditary endometrial cancer pedigrees display significant phenotypic overlap with those of other hereditary cancer syndromes. For example, multiple cases of endometrial cancer and colorectal polyps may be present in a family with Lynch syndrome (associated with mutations in MLH1, MSH2, MSH6, PMS2 and EPCAM) or with Cowden syndrome (associated with mutations in PTEN). A hereditary cancer syndrome diagnosis cannot always be established based upon the pedigree analysis alone. The OncoGeneDx Endometrial Cancer panel tests for genes associated with multiple hereditary cancer syndromes that may present similarly, including Lynch syndrome, Cowden syndrome, Li-Fraumeni syndrome and hereditary breast/ovarian cancer syndrome (BRCA1 and BRCA2). While each of these syndromes is associated with a significantly increased risk of endometrial cancer and other cancers, each syndrome has gene-specific and site-specific cancer risks for which National Comprehensive Cancer Network (NCCN) management recommendations differ1,2. These may include increased cancer surveillance and options for prophylactic surgeries and chemoprevention. Thus, it is essential that an accurate diagnosis is established for this patient in order to determine [HIS_HER] appropriate medical management. Conclusion: Knowledge of this patient's genetic information is important for me to more accurately assess [HIS_HER] cancer risks and will guide my recommendations for [HIS_HER] care. I have chosen to send the patient’s test to GeneDx because this laboratory has highly sensitive, rapid and costeffective genetic testing for hereditary breast and/or ovarian cancer, which will provide helpful medical treatment planning information for my patient. Thank you for your review and consideration. I hope you will support this request for genetic testing coverage for [PATIENT_FIRST_NAME] [PATIENT_LAST_NAME]. If you have questions, or if I can be of further assistance, please do not hesitate to call me at [PHYSICIAN_PHONE_NUMBER]. Sincerely, [PHYSICIAN_FIRST_NAME] [PHYSICIAN_LAST_NAME], MD cc:[PATIENT_FIRST_NAME][PATIENT_LAST_NAME] 1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2015. www.nccn.org. 2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Genetic/Familial High-Risk Assessment: Colorectal. Version 2.2014. www.nccn.org.